Overview
KRT1-related diffuse nonepidermolytic keratoderma (also called diffuse nonepidermolytic palmoplantar keratoderma type Unna-Thost, or simply DNEPK) is a rare inherited skin condition caused by changes in the KRT1 gene. This gene provides instructions for making keratin 1, a protein that helps give skin its strength and structure. When this gene does not work properly, the skin on the palms of the hands and soles of the feet becomes abnormally thick, hard, and rough. This thickening is called keratoderma. The main symptom is a diffuse, even thickening of the skin across the entire surface of the palms and soles, usually without blistering. The skin may appear yellowish and feel very tough. Some people also notice that the thickened skin extends slightly onto the tops of the feet or hands. Sweating in these areas can be increased, which may lead to an unpleasant odor or secondary fungal and bacterial infections. There is currently no cure for this condition. Treatment focuses on managing symptoms, mainly by softening and reducing the thick skin using moisturizers, keratolytic creams (products that help break down thickened skin), and careful physical removal of excess skin. With consistent daily skin care, most people can manage their symptoms and live full, active lives. The condition is lifelong but does not affect internal organs or shorten life expectancy.
Also known as:
Key symptoms:
Thick, hard skin on the palms of the handsThick, hard skin on the soles of the feetYellowish or waxy appearance of the thickened skinSkin thickening that covers the entire palm and sole evenlyIncreased sweating on the palms and solesUnpleasant odor from the affected areasSkin that may crack or become painful, especially on the feetIncreased risk of fungal infections (like athlete's foot) in thickened areasMild extension of thickened skin onto the sides of the feet or hands in some peopleDifficulty with fine hand movements due to skin stiffness
Clinical phenotype terms (15)— hover any for plain English
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for KRT1-related diffuse nonepidermolytic keratoderma.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for KRT1-related diffuse nonepidermolytic keratoderma at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for KRT1-related diffuse nonepidermolytic keratoderma.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to KRT1-related diffuse nonepidermolytic keratoderma.
Community
No community posts yet. Be the first to share your experience with KRT1-related diffuse nonepidermolytic keratoderma.
Start the conversation →Latest news about KRT1-related diffuse nonepidermolytic keratoderma
No recent news articles for KRT1-related diffuse nonepidermolytic keratoderma.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is the best daily skin care routine for managing the thick skin on my palms and soles?,Which moisturizers or keratolytic creams do you recommend, and how often should I use them?,How can I tell if a skin infection is developing, and when should I seek urgent care?,Should other family members be tested for this condition, and what does a positive result mean for them?,Are there any clinical trials or new treatments being studied that I should know about?,What type of footwear or orthotics would help reduce pain and prevent skin breakdown?,Are there any activities or occupations I should avoid because of this condition?
Common questions about KRT1-related diffuse nonepidermolytic keratoderma
What is KRT1-related diffuse nonepidermolytic keratoderma?
KRT1-related diffuse nonepidermolytic keratoderma (also called diffuse nonepidermolytic palmoplantar keratoderma type Unna-Thost, or simply DNEPK) is a rare inherited skin condition caused by changes in the KRT1 gene. This gene provides instructions for making keratin 1, a protein that helps give skin its strength and structure. When this gene does not work properly, the skin on the palms of the hands and soles of the feet becomes abnormally thick, hard, and rough. This thickening is called keratoderma. The main symptom is a diffuse, even thickening of the skin across the entire surface of th
How is KRT1-related diffuse nonepidermolytic keratoderma inherited?
KRT1-related diffuse nonepidermolytic keratoderma follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does KRT1-related diffuse nonepidermolytic keratoderma typically begin?
Typical onset of KRT1-related diffuse nonepidermolytic keratoderma is infantile. Age of onset can vary across affected individuals.